EHA 2016: New Therapeutic Strategies for the Management of Patients with Relapsed-Refractory Multiple Myeloma

PROGRAM OVERVIEW This CME program will cover data on new therapeutic strategies for the management of patients with relapsed-refractory multiple myeloma that were presented at the European Hematology Association 2016 Annual Congress. The expert faculty of this program will discuss tumor science, including relapsed, refractory, and progressive disease. They will discuss the analysis of clinical […]

Continue reading


Maximizing the Therapeutic Potential of Janus Kinase 2 (JAK2) Inhibitors in Patients with Chronic Myelofibrosis

This course is still available as a learning tool but has expired for CME credit. Program Overview The pathobiology of myelofibrosis continues to advance and the current understanding of myelofibrosis is complex. Guidelines and recommendations for the diagnosis of myelofibrosis, including the revised WHO criteria for myelofibrosis, is controversial. The clinical trial data on JAK2 […]

Continue reading